Myrtle Potter is President and Chief Executive Officer of Sumitomo Pharma America (SMPA) and Chairperson of the Board of Sumitomo Pharma UK.
In this role, Myrtle leads a fast-growing, global biopharmaceutical company that has a robust pipeline of innovative drug treatments targeting a broad range of diseases.
Prior to Sumitomo, Myrtle served as Chief Executive Officer of Myrtle Potter & Company from 2005 to 2018, she and her team of experts led major strategic efforts and multiple product launches for numerous global biopharmaceutical companies.
From 2000 to 2004, Myrtle served as Chief Operating Officer at Genentech, Inc., and from 2004 to 2005, she served as President, Commercial Operations, and Executive Vice President. Under her leadership, Genentech’s revenue grew by five times in five years, resulting in record sales and earnings growth for nineteen of twenty consecutive quarters.
Myrtle serves on the Boards of Liberty Mutual Insurance Group and Guardant Health.
Myrtle earned a B.A. degree in Political Science from the University of Chicago and serves on the University’s Board of Trustees.
